Conceptos Categóricos

PATOGENIA, CLINICA Y TRATAMIENTO DE LAS CEFALEAS CRONICAS

PATOGENIA, CLINICA Y TRATAMIENTO DE LAS CEFALEAS CRONICAS

(especial para SIIC © Derechos reservados)
Cefalea crónica es un vocablo descriptivo. El 5% de la población sufre de dolor de cabeza diario o casi diario. Esto indica un grave impacto psicológico, social y económico. Esta cefalea frecuente es el principal motivo de consulta en los centros especializados en dolor de cabeza.
Autor:
Bibiana B. Saravia
Columnista Experta de SIIC

Institución:
Hospital General de Agudos "Ramos Mejía"


Artículos publicados por Bibiana B. Saravia
Recepción del artículo
31 de Julio, 2011
Aprobación
22 de Noviembre, 2011
Primera edición
17 de Febrero, 2012
Segunda edición, ampliada y corregida
7 de Junio, 2021

Resumen
Alrededor del 5% de la población padece de cefaleas durante más de 15 días por mes. Esta situación implica un elevado costo personal y social. Las cefaleas crónicas en su mayoría son migrañas crónicas y es importante que los facultativos tengan la información necesaria para su diagnóstico y tratamiento, de esta forma se evitarán gastos innecesarios en métodos de estudio inadecuados y se podrá aliviar a los pacientes con las estrategias actuales al alcance, ya sean abordajes no farmacológicos o utilizando drogas de reconocida acción, aprobadas para este fin y con pleno conocimiento de sus efectos. En caso de que lo anterior no resulte eficaz, se podrá analizar la posible implementación de tratamientos invasivos, como los implantes de estimuladores u otras técnicas quirúrgicas. En este artículo se efectúa una puesta al día de los conceptos actuales.

Palabras clave
migraña crónica, input cortical, depresión, moduladores neuronales, terapia no farmacológica


Artículo completo

(castellano)
Extensión:  +/-7.33 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Abstract
About 5% of the population suffers headaches more than 15 days a month. This situation implies a high personal and social loss. The majority of chronic headaches are chronic migraines, and it is important that physicians have the necessary information for its diagnosis and treatment. In this way, unnecessary expenses and inappropriate studies can be avoided, and patients can be helped with the current methods, be either non-pharmacological techniques, or approved pharmacological substances of well known effects, used with good knowledge of their actions. If the above does not result helpful, the use of invasive procedures can be entertained, such as implant of stimulators or others surgical techniques. In this report, up to date knowledge in this subject is reviewed.

Key words
chronic migraine, cortical input, depression, neural modulators, non-pharmacological treatment


Clasificación en siicsalud
Artículos originales > Expertos de Iberoamérica >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Neurología
Relacionadas: Anestesiología, Atención Primaria, Educación Médica, Epidemiología, Farmacología, Medicina del Dolor, Medicina Farmacéutica, Medicina Interna



Comprar este artículo
Extensión: 7.33 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Bibiana B. Saravia, Hospital General de Agudos "Ramos Mejía", Buenos Aires, Argentina
Bibliografía del artículo
1) Castillo J, Munoz P, Guitera V, et al.: Epidemiology of chronic daily headache in the general population. Headache 1999, 39:190–196.
2) Scher AI, Stewart WF, Liberman J, et al.: Prevalence of frequent headache in a population sample. Headache 1998, 38:497–506.
3) Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headache: field trial of revised IHS criteria. Neurology 1996; 47:871-875.
4) Mathew NT. Transformed migraine. Cephalalgia. 1993;13(Suppl. 12):78-83.
5) Mathew NT, Stubits E, Nigam MP. Transformation of episodic migraine into daily headache:Analysis of factors. Headache. 1982;22:66-68.
6) Mathew NT, Reuveni U, Perez F. Transformed or evolutive migraine. Headache. 1987;27:102-106.
7) Silberstein SD, Lipton RB, Solomon S, Mathew NT. Classification of daily and near-daily headaches: Proposed revisions to the IHS criteria. Headache. 1994;34:1-7.
8) Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches: Field trial of revised IHS criteria. Neurology. 1996;47:871-875.
9) Manzoni GC, Granilla F, Sandrini G, Cavallini A, Zanferrari C, Nappi G. Classification of chronic daily headache by International Headache Society criteria: Limits of new proposal. Cephalalgia. 1995;15:37-43.
10) Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders. Cephalalgia. 2004; 24:1-160.
11) Olesen J. International Classification of Headache Disorders, 2nd edn (ICHD-2): Current status and future revisions. Cephalalgia. 2006;26:1409-1410.
12) Olesen J. New plans for headache classification: ICHD-3. Cephalalgia 2011 31: 4.
13) Olesen J. Bousser M-G, Diener H-C, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006; 26: 742–746.
14) Manack A, Turkel C, Silberstein S. The Evolution of Chronic Migraine: Classification and Nomenclature. Headache 2009; 49:1206-1213.
15) Welch KMA, Nagesh V, Aurora SK, Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of the illness? Headache. 2001; 42:629-637.
16) Welch KMA, Nagesh V, Aurora SK, Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of the illness? Headache. 2001; 42:629-637.
17) Borkum JM. Chronic Headaches and the Neurobiology of SomatizationCurr Pain Headache Rep (2010) 14:55–61.
18) Schweinhardt P, Kuchinad A, Pukall CF, Bushnell MC: Increased gray matter density in young women with chronic vulvar pain. Pain 2008, 140:411–419.
19) Schmidt-Wilcke T, Leinisch E, Gänßbauer S, et al.: Affective components and intensity of pain correlate with structural differences in gray matter in chronic back pain patients. Pain 2006, 125:89–97.
20) Bigal ME, Lipton RB: What predicts the change from episodic to chronic migraine? Curr Opin Neurol 2009, 22:269–276.
21) Vikelis M, Mitsikostas DD: The role of glutamate and its receptors in migraine. CNS Neurol Disord Drug Targets 2007, 6:251–257.
22) Silberstein SD, Lipton RB, Dodick DW: Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007, 47:170–180.
23) Young WB, Mateos V, Ashkenazi A: Occipital nerve block rapidly eliminates allodynia far from the site of headache: a case report. Cephalalgia 2004, 24:906–907.
24) Matharu MS, Bartsch T, Ward N, et al.: Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain 2004, 127:220–230.
25) Goadsby PJ, Bartsch T, Dodick DW: Occipital nerve stimulation for headache: mechanisms and efficacy. Headache 2008, 48:313–318.
26) Baskin SM, Lipchik GL, Smitherman TA. Mood and Anxiety Disorders in Chronic Headache. Headache 2006;46(Suppl 3):S76-S87.
27) Lipchik GL, Penzien DB. Psychiatric comorbidities in patiens with headache. Semin Pain Med. 2004;2:93-105.
28) Lipchik GL, Penzien DB. Psychiatric comorbidities in patiens with headache. Semin Pain Med. 2004;2:93-105.
29) Merikangas KR, Angst J, Isler H. Migraine and psychopathology. Arch Gen Psychiatry. 1990;47:849-853.
30) Lake AE, Rains JC, Penziens DB, Lipchik GL. Headache and psychiatric comorbidity: Historical context, clinical implications, and research relevante. Headache. 2005;45:493-506.
31) Radat F, Swendsen J. Psychiatric comorbidity in migrain: A review. Cephalalgia. 2004;25:165-178.
32) Natesh S, Rajashekhara SK, Rao ASD, Shetty B. Topiramate-induced angle closure with acute myopia, macular striae. Oman J Ophthalmol. 2010 Jan–Apr; 3(1): 26–28.
33) Akbarian MA, Mehrpour M. A Case report on toriramate induced myopia. Ir j pharma and therap.2004;3:66–7.
34) Spaccapelo L, Leschiutta S, Aurea C, Ferrari A. Topiramate-associated acute glaucoma in a migraine patient receiving concomitant citalopram therapy: A case-report. Cases J. 2009;2:87.[PMCID: PMC2637258] [PubMed: 19171058].
35) Fraunfelder FW, Fraunfelder FT, Keates EU. Topiramate-associated acute, bilateral, secondary angle-closure glaucoma. Ophthalmology. 2004;111:109–11. [PubMed: 14711721].
36) Newman LC, Broner SW, Lay CL. Reversible anorgasmia with topiramate therapy for migraine. Neurology 2005;65;1333-1334.
37) Holtkamp M, Weissinger F, Meierkord H. Erectile dysfunction with topiramate. Epilepsia 2005;46:166–167.
38) Tilz C, Wang-Tilz Y, Jünemann A, Stefan H, Michelson G. Visual field defect during therapy with valproic-acid. Eur J Neurol 2007;14:929–32.
39) Olerud B, Gustavasson CL. Nadolol and propanolol in migraine management. Headache 1986;26:490–493.
40) Stein DJ, Hollander E. Sexual dysfunction associated with the drug treatment of psychiatric disorders: incidence and treatment. CNS Drugs 1994;2:78–86.
41) Silberstein SD. Preventive headache treatment. Cephalalgia 1997;17:67–72.
42) Vargas BB. Chronic Migraine: Current Pathophysiologic Concepts as Targets for Treatment. Current Pain and Headache Reports 2009, 13:64–66.
43) Johannessen Landmark C. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 2008;22:27-47.
44) Ashkenazi A, Benlifer A, Korenblit J, et al. Zonisamide for migraine prophylaxis in refractory patients. Cephalalgia 2006;26:1199-1202.
45) Peres MF, Zukerman E, Senne Soares CA, et al. Cerebrospinal fluid glutamate levels in chronic migraine. Cephalalgia 2004;24:735-739.
46) Luo ZD, Chaplan SR, Higuera ES, et al. Upregulation of dorsal root ganglion alpha-2 delta calcium channel subunit and its correlation with allodynia in spinal nerve injured rats. J Neurosci 2001;21:1868-1875.
47) Wang H, Bolognese J, Calder N, et al. Effect of morphine and pregabalin compared with diphenhydramine hydrochloride and placebo on hyperalgesia and allodynia induced by intradermal capsaicin in healthy male subjects. J Pain 2008;9(12):1088-1095.
48) Fehrenbacher JC, Taylor CP, Vasko MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 2003;105:133-141.
49) Calandre EP, Garcia-Leiva JM, Rico-Villademoros F, et al. Pregabalin in the treatment of chronic migraine: an open-label study. Clin Neuropharmacol 2009;33:35-39.
50) Rizzato B, Leone G, Misaggi G, Zivi I, Diomedi M. Efficacy and Tolerability of Pregabalin Versus Topiramate in the Prophylaxis of Chronic Daily Headache With Analgesic Overuse: An Open-Label Prospective Study Clin Neuropharm 2011;34: 74-78.
51) Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain 2001;89:107-110.
52) Goadsby PJ, Dodick D, Mitsias P, Khan K, Khan A, Brewer AR et al. ONSTIM: occipital nerve stimulation for the treatment of chronic migraine. Eur J Neurol 2005; 12 (Suppl. 2):198.
53) Franzini A, Ferroli P, Leone M, Broggi G. Stimulation of the posterior hypothalamus for treatment of chronic intractable cluster headaches. The first reported series. Neurosurgery 2003 52:1095-101.
54) Dodick DW, Trentman T, Zimmerman R, Eross EJ. Occipital nerve stimulation for intractable chronic primary headache disorders. Cephalagia 2003; 23:701.

 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
-->